Hikal (NSE:HIKAL) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:HIKAL Hikal Ltd NSE:HIKAL
73 GF Score
Price ₹217.99
GF Value ₹271.79
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Hikal Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.


NSE:HIKAL vs ZTS: Short Interest Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Hikal's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hikal Short Interest vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hikal's Short Interest distribution charts can be found below:

* The bar in red indicates where Hikal's Short Interest falls into.


NSE:HIKAL
73GF Score
Hikal Ltd NSE:HIKAL
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hikal (NSE:HIKAL) Overvalued in 2026?

Based on GuruFocus' analysis, Hikal stock appears to be undervalued. The current stock price of ₹217.99 is trading 19.8% below its estimated GF Value™ of ₹271.79. GuruFocus considers Hikal to be Modestly Undervalued.

Key valuation signals for NSE:HIKAL:

  • Short Interest:
  • GF Value™: ₹271.79 vs. price of ₹217.99 (19.8% below fair value)
  • GF Score™: 73/100 with 5 warning signs

No single metric tells the full story. See the NSE:HIKAL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hikal Business Description

Other Exchanges 524735:India
Address Great Eastern Chambers, 6th Floor, Sector 11, CBD Belapur, Navi Mumbai, MH, IND, 400 614
Hikal Ltd manufactures chemical intermediates, specialty chemicals, active pharmaceutical ingredients, and contract research activities. Its products are distributed to the pharmaceutical, biotech, agrochemical, and specialty chemical industries. Its segments include Crop Protection and Pharmaceuticals. The majority of the revenue is derived from the pharmaceutical segment.
73GF Score

Get the complete analysis for NSE:HIKAL

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹217.99
Price
₹271.79
GF Value